Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high‐risk localized prostate cancer-Reference-Cited by-同舟云学术

Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high‐risk localized prostate cancer

Published:2021-03-23 Issue:7 Volume:81 Page:418-426
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Graham Laura S.¹²^ORCID,True Lawrence D.³,Gulati Roman²,Schade George R.⁴,Wright Jonathan⁴,Grivas Petros¹²,Yezefski Todd¹²,Nega Katie¹,Alexander Katerina²,Hou Wen‐Min²,Yu Evan Y.¹²,Montgomery Bruce¹⁵,Mostaghel Elahe A.¹²⁵,Matsumoto Alvin A.⁵,Marck Brett⁵,Sharifi Nima⁶,Ellis William J.⁴,Reder Nicholas P.³⁷,Lin Daniel W.⁴,Nelson Peter S.¹⁸,Schweizer Michael T.¹²

Affiliation:

1. Division of Oncology, Department of Medicine University of Washington Seattle Washington USA

2. Clinical Research Division, Fred Hutchinson Cancer Research Center Seattle Washington USA

3. Department of Laboratory Medicine and Pathology University of Washington Seattle Washington USA

4. Department of Urology University of Washington Seattle Washington USA

5. Geriatric Research Education and Clinical Care, VA Puget Sound Health Care System Seattle Washington USA

6. Genitourinary Malignancies Research Center, Cleveland Clinic Cleveland Ohio USA

7. Department of Mechanical Engineering University of Washington Seattle Washington USA

8. Division of Human Biology, Fred Hutchinson Cancer Research Center Seattle Washington USA

Funder

Janssen Pharmaceuticals

Prostate Cancer Foundation

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24118

Reference32 articles.

1. Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy

2. Prostate Cancer–Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era

3. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

4. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up

5. NEOADJUVANT ANDROGEN ABLATION BEFORE RADICAL PROSTATECTOMY IN cT2bNxMo PROSTATE CANCER: 5-YEAR RESULTS

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer;Endocrine-Related Cancer;2024-04-29

2. AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies;Frontiers in Pharmacology;2024-03-08

3. Genitourinary cancer neoadjuvant therapies: current and future approaches;Trends in Cancer;2023-12

4. Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial;Clinical Cancer Research;2023-07-13

5. Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review;Journal of Personalized Medicine;2023-04-07